VIDAS® Lyme panel

Differential diagnosis of Lyme Borreliosis

The combined use of the automated VIDAS® Lyme IgM and VIDAS® Lyme IgG assays will help you provide patients with reliable, differential diagnosis of Lyme borreliosis in just 27 minutes

• Clear-cut results

• High specificity and sensitivity

• Specific detection of IgG antibodies to Borrelia burgdorferi sensu lato (sl) and in cerebro-spinal fluid (CSF) samples, to aid in the diagnosis of Neuroborreliosis*

OVERVIEW

Transmitted through the bite of infected ticks, Lyme Borreliosis is the most common and rapidly spreading tick-borne disease in the world. However many of the symptoms can also occur with other diseases. VIDAS® Lyme IgM and VIDAS® Lyme IgG allow accurate, rapid, differential diagnosis to avoid misdiagnosis and help prevent progression of the disease towards severe and disabling neurological, cutaneous or articular manifestations.

Clear-cut serological profile

• Separate IgG and IgM results to facilitate classification of Lyme Borreliosis as early or late/chronic, active or immune

• Helps ensure patients receive rapid, optimized treatment depending on their stage of infection

• Easy result interpretation:

• No equivocal zone for VIDAS Lyme IgG results

• Avoids unnecessary patient anxiety and limits additional testing

High specificity and sensitivity*

• The tests use innovative recombinant chimeric proteins* (VlsE, DbpA, OspC), allowing detection of all main pathogenic Borrelia strains

• Less rework and confirmatory tests

• Low level of cross-reaction with syphilis and other infectious diseases*

• Only patients with Lyme Borreliosis are treated

Cost-effectiveness and streamlined workflow

VIDAS® Lyme IgM and VIDAS® Lyme IgG are performed on the VIDAS® automated immunoanalyzers, appreciated worldwide for their simplicity, flexibility and accuracy.

Key benefits:

• Ease-of-use

• Rapid results: only 27 minutes

• Protocol compatibility between both tests

• Single-dose format

• Calibration only once every 28 days

TECHNICAL DETAILS

*for references outside US and Canada only

RESOURCES

Related Publications

• Usefulness of quantitative IgG assays Borrelia VLSE LIAISON® and the new VIDAS® Lyme for serological follow-up of patients with Lyme borreliosis

• O. Péter, R. Lienhard, R. Vonlanthen, A. Bonnet-Pierroz, C. Béguelin, A. Schaller, D. Genne (Switzerland)

• Poster | ECCMID 2014

• Performance evaluation of the new VIDAS Lyme IgM and IgG assays compared to the previous VIDAS Lyme total antibodies assay on fresh prospective sera

• S. Neifer, O. Wankmüller (Germany)

• Poster | ECCMID 2012

• Evaluation of two automated tests on the VIDAS® system to detect anti-Lyme disease antibodies IgG and IgM in human serum, plasma and CSF

• G. Bouchard, O. Péter, A. Bonnet-Pierroz, R. Vonlanthen, P. Cosin, N. Ammour, A. M. Brevet, P. Broquedis, N. Dehainault, C. Perret, B. Inçaurgarat (France, Switzerland)

• Poster | ECCMID 2010

Useful Links

• ESCMID Study Group for Lyme Borreliosis - ESGBOR

• Centers for Disease Control and Prevention | Resources for Clinicians